Compare McDonald's Corp (MCD) vs Merck & Co., Inc. (MRK) Price & Performance

McDonald's stock trades at $267.64, down slightly by 0.03% on the day, and is currently in a bearish technical trend according to moving averages. The company reported Q1 2026 earnings that beat expectations with EPS of $2.83 versus $2.74 expected, and revenue growth remains steady, reaching $26.89 billion in 2025. Recent news highlights the launch of the 'McDonald's NEXT' growth strategy focusing on automation and improved customer experience to counter competitive pressures.

The outlook for McDonald's is supported by strong fundamentals including a high net income margin of 31.62% and a consensus analyst price target of $329, implying significant upside. However, risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. Investor sentiment is mixed with a bearish technical signal but optimistic analyst ratings, with 58% recommending buy.

Merck (MRK) trades at $127.5, down slightly (-0.14%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

The outlook for MRK is positive, supported by earnings momentum, strategic acquisitions, and strong analyst buy ratings (67.57%). Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the pharmaceutical sector. The stock offers a dividend yield with a recent $0.85 per share payment, appealing for income-focused investors amid steady revenue growth.